Therefore, in the present study, the classic IBD drug 5-aminosalicylic acid (5-ASA) as a positive control drug is used to evaluate the therapeutic effect of SSP [8–10], and we want to assess whether SSP could alleviate TNBS-induced UC by maintaining the integrity of the intestinal mucosal barrier via regulating Rho/ROCK signaling pathway. Here, RHO is linked to inflammatory bowel disease.